Cats with heart disease (Hypertrophic cardiomyopathy)

Print PDF

Pre-screening surveyEmail us!     

Purpose and Brief Explanation of Study:

Cardiogenic embolism is a common sequela of heart muscle disease (cardiomyopathy) in cats leading to debilitating clinical signs including severe pain, neurologic deficits, renal failure, congestive heart failure, and death. Feline thromboembolic disease is predisposed by left atrial enlargement and dysfunction, leading to blood stasis and thrombus formation.

 

This study will test the hypothesis that Pimobendan, a drug that enhances myocardial contractility and reduces cardiac workload, will increase left atrial transport function, accelerate intracardiac blood flow, and thus reduce blood stasis in cats with hypertrophic cardiomyopathy (HCM) and left atrial enlargement. If confirmed, Pimobendan may become as a novel treatment option in the prevention of thromboembolic disease in cats with cardiomyopathy. It is currently a standard of care in dogs with cardiac disease and congestive heart failure and less commonly in cats, but prescribed for various reasons such as end-stage congestive heart failure.

 

Objective of the trial:

The goal of this study is to prove that Pimobendan improves left atrial function and thus prevents stagnating blood flow, possibly preventing the development of thromboembolic disease, a common and often deadly consequence of hypertrophic cardiomyopathy.

What qualifies my cat for enrollment in this in this trial?

To participate in this clinical trial your cat must have:

  • A diagnosis of hypertrophic cardiomyopathy (non-obstructive form of disease)
  • Normal thyroid level, normal blood pressure, normal red blood cell count
  • Ability to medicate twice daily (capsule can be opened and mixed with water in a syringe or food)
  • Ability to return to The OSU-VMC in 4-7 days from initial Cardiology visit

What does enrolling my cat in this clinical trial involve?

Procedures (2 visits, 4 to 7 days apart):

Visit # 1:

  • Physical examination
  • Non-invasive blood pressure measurement
  • Blood draw for biochemical analysis of a renal panel, total thyroxin concentration, and PCV/TS
  • Transthoracic echocardiography
  • Sedation (intramuscular injection of a mild sedative)
  • Thoracic radiography (only in cats with suspected congestive heart failure)

Visit #2 (after 4-7 days):

  • Physical examination
  • Non-invasive blood pressure measurement
  • Transthoracic echocardiography
  • Sedation (intramuscular injection of a mild sedative)

Client Compensation

The costs covered by the study include a discount on the initial echocardiogram and visit (about $200-$250), the entire recheck exam and diagnostics (free to client), and there will be a $100 incentive towards future recheck visits at The OSU-VMC.

Client Contact

If you believe your pet may be eligible to enter this study, please click here to fill out a questionnaire. 

Dr. Kochie, kochie.1@osu.edu